A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

← catalyst calendar

NCT07525206 · readout ≤ 1,016 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

700estimated

Sites

Countries

Belgium, Greece, Japan +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-22

actual

When the study began enrolling

Primary completion

May 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2030

estimated

The whole study's end, after follow-up

First posted

2026-04-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Colorectal Cancer

Interventions

Drug: Telisotuzumab adizutecan
Drug: Bevacizumab
Drug: Trifluridine/Tipiracil

Primary outcomes

what the primary-completion date above is the date OF

Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)

measured Up to Approximately 15 Months

Phase 3: Overall Survival (OS)

measured Up to Approximately 36 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed